



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

CH7057288

Cat. No.:	HY-107362		
CAS No.:	2095616-82-1		
Molecular Formula:	C ₃₂ H ₃₁ N ₃ O ₅ S		
Molecular Weight:	569.67		
Target:	Trk Receptor		
Pathway:	Neuronal Signaling; Protein Tyrosine Kinase/RTK		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 34 mg/mL (59.68 mM)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.7554 mL	8.7770 mL	17.5540 mL
	5 mM		0.3511 mL	1.7554 mL	3.5108 mL
	10 mM		0.1755 mL	0.8777 mL	1.7554 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.75 mg/mL (4.83 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	CH7057288 is a potent and selective TRK inhibitor. CH7057288 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAC) with molecules containing Azide groups.
IC ₅₀ & Target	TRK
In Vitro	CH7057288 induces regression of intracranial tumors and greatly improves event-free survival in an intracranial implantation model mimicking brain metastasis. CH7057288 can be a promising therapeutic agent for TRK fusion-positive cancer. TRK receptor tyrosine kinases are expressed as fusion proteins encoded by various fusion genes across a wide variety of cancer types, including lung and colorectal cancer ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Hiroshi Tanaka, et al. Abstract 4179: Potent and selective TRK inhibitor CH7057288. AACR Annual Meeting 2017; April 1-5, 2017.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA